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Sulnmary 
The  mouse  mast  cell  protease  granule  tryptases  designated  mMCP-6  and  mMCP-7  are  en- 
coded by highly homologous genes that reside on chromosome 17. Because these proteases are 
released when mast ceils are activated, we sought a basis for distinctive functions by examining 
their fates in mice undergoing passive systemic anaphylaxis.  10 rain-1  h  after antigen  (Ag) was 
administered to immunoglobulin  (Ig)E-sensitized mice, numerous protease/proteoglycan mac- 
romolecular complexes appeared in the extracellular matrix adjacent to most tongue  and heart 
mast  cells  of normal  BALB/c  mice  and  most  spleen  and  liver mast  cells  of V3  mastocytosis 
mice.  These  complexes  could  be  intensively  stained  by  anti-mMCP-6  Ig but  not  by  anti- 
mMCP-7  Ig.  Shortly  after Ag challenge  of V3  mastocytosis mice,  large amounts  of properly 
folded,  enzymatically  active  mMCP-7  were  detected  in  the  plasma.  This  plasma-localized 
tryptase was ,'-,150 kD in its multimeric state and "o32 kD in its monomeric state, possessed an 
NH2 terminus identical to that of mature mMCP-7,  and was not covalently bound to any pro- 
tease  inhibitor.  Comparative  protein  modeling  and  electrostatic  calculations  disclosed  that 
mMCP-6  contains  a  prominent  Lys/Arg-rich  domain  on  its  surface,  distant  from the  active 
site. The absence of this domain in mMCP-7 provides an explanation for its selective dissocia- 
tion from the exocytosed macromolecular complex.  The retention  of exocytosed mMCP-6  in 
the extracellular matrix around activated tissue mast cells suggests a local action. In contrast, the 
rapid dissipation  ofmMCP-7  from granule cores and its inability to be inactivated by circulat- 
ing protease inhibitors suggests that this tryptase cleaves proteins located at more distal sites. 
A 
family of trypsin-like serine proteases  is a  major con- 
stituent of the secretory granules of certain populations 
of mast cells in mice (1--4) and humans  (5-9).  Two mouse 
tryptases  (designated  mouse mast cell protease  [mMCP] 1 6 
[2] and mMCP-7  [3]), whose genes reside on chromosome 
17 (10,  11), have amino acid sequences that are 71% identi- 
cal.  The  airway responsiveness  of the  C57BL/6  mouse  to 
acetylcholine and 5-hydroxytryptamine is very low relative 
IAbbreviations used in this paper: FPLC, fast protein liquid chromatography; 
mt3MMC, mouse bone marrow-derived mast cell; mMCP, mouse mast 
cell protease; V3-MC, V3 mast cell. 
to  other  mouse  strains  (12),  and  linkage  analysis  (13)  has 
implicated  the  region  of  chromosome  17  where  the 
mMCP-6 and mMCP-7 genes reside as one of three candi- 
date  loci  for  the  inheritance  of intrinsic  airway  hyperre- 
sponsiveness.  The  observation  that  the  C57BL/6  mouse 
cannot express mMCP-7  because its gene possesses a point 
mutation  at its  exon  2/intron  2  splice  site  (14)  suggests  a 
role of mMCP-7  in airway responsiveness.  The additional 
finding that two low molecular weight inhibitors  of tryptic 
enzymes  block Ag-induced  airway  constriction  and  tissue 
inflammatory responses in Ascaris suum-sensitized sheep  (15) 
supports the involvement of the tryptase family of mast cell 
proteases  in  the  pathobiology  of Fc~RI-elicited  responses 
in  airways.  Mast  cell  tryptases  can  induce  airway  smooth 
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smooth muscle relaxation  induced by vasoactive intestinal 
peptide in the ferret (17), and induce proliferation offibro- 
blasts  (18)  and epithelial  cells  (19).  Their physiologic sub- 
strates  remain  to  be  established;  but  in  vitro  studies  have 
identified a number of susceptible substrates, including high 
molecular weight kininogen (20), vasoactive intestinal pep- 
tide  (21),  matrix pro-metalloproteinase-3  (22),  pro-uroki- 
nase  (23),  fibronectin  (24,  25),  fibrinogen  (26),  and  the 
complement protein C3 (27).  That m/VlCP-6 and mMCP-7 
have been implicated in airway reactivity prompted a more 
detailed  consideration  of the  in  vivo  fate  of these  two 
tryptases after their exocytosis from tissue mast cells. 
The secretory granules of mast cells possess a pH of~5.5 
(28). As a consequence, the 26-32-kD mMCPs that reside 
in  secretory  granules  are  positively  charged  and  ionically 
bound  to  the  various  negatively  charged  serglycin  pro- 
teoglycans in this intracellular  compartment.  Even at neu- 
tral pH,  most mouse  (1,  29),  rat  (30),  and human  (31,  32) 
granule  proteases  bind  so  strongly to  serglycin proteogly- 
cans  that  at  least  some  of the  macromolecular  complexes 
exocytosed from mast cells  activated by compound 48/80 
or  by  cross-linking  of their  high  affinity  IgE  receptors 
(FceRI) remain intact outside of the cells  for extended pe- 
riods  of time.  Granule  cores  or remnants,  reflecting pro- 
tease/proteoglycan  macromolecular  complexes  of  unde- 
fined composition, have been observed outside of activated 
mast  cells  in  tissues  (33,  34)  and  in  coculture  with  fibro- 
blasts  (35).  The functional roles of the protease/proteogly- 
can macromolecular complexes  remain  to be  determined, 
but serglycin proteoglycans have been reported to stabilize 
mast cell tryptases  (31, 36)  and alter the substrate  specifici- 
ties of mast cell tryptases and chymases (27, 37, 38). 
Protein structure  modeling and electrostatic  calculations 
have  been  carried  out  for  four  chymases  (mMCP-1, 
mMCP-2, mMCP-4, and mMCP-5)  and the tryptase des- 
ignated  mMCP-7  (4,  39,  40).  mMCP-4  and  mMCP-5 
were  predicted  to  have  two  regions  with  net  positive 
charges ranging from +6 to  +10 at neutral pH located at 
opposite  ends  of each  molecule  and  away from the  sub- 
strate-binding cleft (39). mMCP-1, mMCP-2, and mMCP-7 
are predicted to have only one of these regions. The puta- 
tive  glycosaminoglycan-binding regions  in  the  four  mast 
cell chymases are rich in Lys/Arg with at most one His res- 
idue.  In  contrast,  the  corresponding  region  in  mMCP-7 
has five His residues.  Thus,  in distinction to the chymases, 
the strong positive potential on one face ofmMCP-7 is di- 
minished at neutral pH where the His residues do not have 
a positive charge. Site-directed mutagenesis of recombinant 
pro-mMCP-7 showed that the mutation of His  8, His  68, or 
His  7~ into a Glu residue in the identified positively charged 
region prevents its binding to heparin at pH 5.5 (40). These 
in  vitro  observations  raised  the  possibility  that  mMCP-7 
might selectively dissociate  from its  proteoglycan/protease 
macromolecular complexes in vivo after  exocytosis into  a 
neutral  pH  environment  such  as  the  extracellular  milieu. 
To  test this  hypothesis,  we  examined  the fate  of two ho- 
mologous  but  distinct  tryptases  exocytosed  in  vivo  from 
Fc~RI-activated mouse mast cells. 
Materials and Methods 
FceRI-mediated Activation of Mast Cells in  V3  Mastocytosis Mice 
and in Normal BALB/c Mice.  To create a V3 mastocytosis mouse, 
~106  cultured V3 mast  cells (V3-MC),  maintained in enriched 
RPMI-1640 medium as described  previously (41), were injected 
intravenously into  the  tail  vein  of a  6-wk-old BALB/c mouse 
(The Jackson Laboratory, Bar Harbor, ME). V3 mastocytosis mice 
were used 2-4 wk after the adoptive transfer  of V3-MC. Anti- 
TNP IgE was diluted in HBSS to a final concentration of 1 mg/ml, 
and V3 mastocytosis  and normal BALB/c mice were each sensi- 
tized with 200 I~g IgE i.p.  Alternatively,  each mouse was sensi- 
tized with 100 I*1 i.p. of an ascites fluid preparation oflgE. Ascites 
IgE was titered for activity by passively sensitizing mice and mon- 
itoring plasma histamine  levels 15 rain after administration  of Ag 
(TNP-BSA). The dose of ascites used in the in vivo experiments 
mediated a level  of histamine  release comparable with  that ob- 
tained  with 200 btg of purified IgE. 24 h  after passive sensitiza- 
tion,  TNP-BSA in ~300  I*1 of HBSS was injected intraperito- 
neally into each mouse.  Normal sensitized mice generally received 
1,000 I~g Ag. Depending on the extent of the disease, the amount 
of Ag given to an IgE-sensitized  V3 mastocytosis  mouse varied 
from 10 to 1,000  ~xg. The IgE and Ag dosages used in each ex- 
periment  produced  obvious  symptoms  of mast  cell  activation 
(e.g., labored breathing and decreased  movement) but no mortal- 
ity.  10 rain-24 h  after Ag administration,  100-500 b~l of blood 
was obtained from the retroorbital plexus  with a Pasteur  pipette 
pretreated with an anticoagulant.  Each plasma sample  contained 
either 25  U  of heparin glycosarninoglycan  (Elkins-Sinn,  Cherry 
Hill,  NC)  or 10 mM EDTA. Samples were centrifuged for 3-5 
min at ~10,000 g at 4~ 
Preparation ofAnti-mMCP-6 Ig.  The preparation and specific- 
ity of anti-mMCP-6  Ig has  not been  described,  but this  rabbit 
anti-peptide Ab was used in the initial characterization  of the V3 
mastocytosis  mouse  (41). Although the  overall  amino  acid  se- 
quences ofmMCP-6 and mMCP-7 are 71% identical  (2-4), areas 
of greater  dissimilarity  are  present  in  the  tryptases.  Since  a 
mMCP-7-specific Ab was previously obtained in rabbits  with a 
synthetic 19-mer peptide (designated  peptide 7) that corresponds 
to residues  160-178 (42), an Ab was prepared against a synthetic 
peptide  (designated  peptide 6) that corresponds to the analogous 
region in mMCP-6 (Fig. 1 A). As assessed by the Protein Iden- 
tification  Resource database of the National Biomedical Founda- 
tion (Bethesda, MD), peptide 6 (Arg-Lys-Try-His-Thr-Gly-Leu- 
Try-Thr-Gly-Asp-Asp-Phe-Pro-Ile-Val-His-Asp-Gly)  is not present 
in any other mouse protein. This peptide was synthesized by Bio- 
serv Labs (San Jose,  CA) coupled to an octavalent  Lys resin.  A 
New Zealand White rabbit  was injected intramuscularly  with an 
emulsion consisting  of 0.5 nil of the coupled peptide  (N500 ixg) 
mixed  with  an  equal  volume  of TiterMax  synthetic  adjuvant 
(CyRx Corp.,  Norcross, GA).  The  immunized rabbit  received 
booster injections  intramuscularly  4 and 12 wk later,  and its se- 
rum was  then collected at biweekly intervals  over a number of 
months. To purify anti-mMCP-6 Ig, a ,'-~20-~g portion of pep- 
tide 6 was coupled at 4~  to 4 ml of Atti-Gel 10 (Bio-Rad Labo- 
ratories,  Richmond, CA) in 0.1 M  sodium bicarbonate, pH 8.5. 
An affinity column was prepared by equilibrating  the resin with 
16 mM boric acid/0.15 M NaCI, pH 8.0. A 10-ml sample of an- 
tiserum was applied,  and the bound Ab was eluted with 10 ml of 
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ethylamine, pH 11.0, into a neutralizing  buffer of 2 M Tris-HCl, 
pH  8.0.  The  collected fractions  were  pooled,  dialyzed  against 
PBS, and stored at -20~  As assessed by SDS-PAGE, the result- 
ing affinity-purified  Ab consisted primarily of IgG. This rabbit Ab 
reacted with peptide 6 in an ELISA at an >10,000-fold dilution. 
The concentration of affinity-purified anti-mMCP-6 Ig was esti- 
mated by optical density. Relative to mature mast cells (1), mouse 
bone marrow-derived mast  cells (mBMMC)  contain very low 
amounts of serine protease  (24). Nevertheless,  SDS-PAGE/im- 
munoblot analysis revealed that affinity-purified  anti-mMCP-6 Ig 
recognized an "o32-kD protein in lysates of 1-2 ￿  106 BALB/c 
mBMMC (Fig. 1 B) developed with IL-3-enriched conditioned 
medium (43). The 32-kD protein was not recognized by preim- 
mune serum (data not shown), and reactivity could be blocked by 
preincubation of the antiserum with peptide 6 but not with the 
peptide that corresponds  to the homologous region in mMCP-7 
(Fig. 1 B). Using the same cell equivalents,  the sensitivity of the 
SDS-PAGE/immunoblot  assay with anti-mMCP-6 Ig was found 
to be comparable with that obtained with anti-mMCP-7 Ig (42). 
Immunohistochemical and Histochemical Analyses of FceRl-activated 
Tissue  Mast  Cells  of Normal  BALB/c  Mice  and  V3  Mastocytosis 
Mice.  For  immunoalkaline phosphatase  staining (44), isolated 
tissues were fixed for 4 h at room temperature in 4% paraformal- 
dehyde and 0.1 M  sodium phosphate,  pH 7.6  (45). Preparations 
were washed twice with PBS  containing 2% DMSO  and then 
were suspended in 50 mM NH4C1 overnight at 4~  The speci- 
mens were dehydrated and embedded in accordance with the JB-4 
embedding kit instructions from Polysciences  Inc. (Warrington, 
PA).  After  1-2  d  of hardening, 1.5-p.m-thick sections  of fixed 
and embedded tissue were cut on a Reichert-Jung Supracut mi- 
crotome (Leica, Deerfield,  IL) with glass knives and picked up on 
glass slides. The slides were incubated sequentially for 15 rain at 
37~  in 2 mM CaC12 containing 0.025%  pancreatic  trypsin,  for 
15 rain at room temperature in PBS containing  0.05% Tween-20 
and 0.1%  BSA,  for  30  min at  37~  in PBS  containing 0.05% 
Tween-20 and 4% normal goat serum, and overnight at 4~  in 
4%  normal goat  serum containing affinity-purified rabbit anti- 
mMCP-6 Ig or anti-mMCP-7 Ig (42). The samples were washed 
and incubated for 40 rain at room temperature in buffer contain- 
ing biotin-labeled goat  anti-rabbit IgG. Each  was washed  twice 
in 0.1% BSA and 0.05% Tween-20 in PBS, incubated for 40 min 
at room temperature in Vectastain ABC-AP reagent (Vector Lab- 
oratories,  Inc., Burlingame, CA), and then incubated for  15 min 
in the dark at room temperature in an alkaline phosphatase  sub- 
strate solution. Controls consisted  of sections of tissue from nor- 
mal mice and V3 mastocytosis mice treated with nonimmune  IgG 
(Endogen, Inc., Boston, MA) or without primary Ab. Tissue sec- 
tions were counterstained with Gill's hematoxylin in 20% ethyl- 
ene glycol, and then coverslips with ImmuMount (Shandon, Inc., 
Pittsburgh, PA) were applied. 
For  histological  examination,  serial  1.5-p.m-thick  glycol- 
methacrylate-embedded sections  of various  tissues from normal 
BALB/c  mice and from V3  mastocytosis  mice were placed  on 
coverslips or slides, air dried,  and stained for 20 s in a 5% ethan- 
olic solution of methylene blue (46). Alternatively, sections were 
incubated sequentially with  double-strength hematoxylin for  2 
rain, 1% aqueous eosin Y for 15 rain, azure II for 1 rain, and eth- 
ylene glycol monomethyl ether for 5 s. 
SDS-PAGE/Immunoblot  Analysis  of Plasma for Mast Ceil  Tryp- 
tases and Characterization of Plasma-localized mMCP- 7.  Samples  of 
plasma ("-'5 ILl) or BALB/c mBMMC lysates (~106 cell equiva- 
lents) were diluted 1:5 vol/vol in SDS-PAGE buffer (1% SDS, 
5% 2-ME, 0.1% bromophenol blue, and 500 mM Tris-HC1,  pH 
6.8)  and boiled for 5 min before being loaded onto 12% poly- 
acrylamide  gels. After SDS-PAGE,  the  resolved  proteins were 
transferred in 20 mM Tris-HC1,  150 mM glycine, pH 8.3 buffer 
containing  20% methanol for 2-4 h at 200 mA to an Immobilon- 
P membrane (Millipore Corp., Bedford,  MA) using an immuno- 
blotting apparatus  (Bio-Rad  Laboratories).  The  resulting blots 
were preincubated in blocking solution (Bio-Rad Laboratories) 
for at least 4 h at 4~  Anti-mMCP-6 Ig or anti-mMCP-7 Ig was 
then added, and each blot was incubated overnight at room tem- 
perature in a sealed plastic bag.  After three 30-rain washes, the 
secondary Ab (diluted in blocking solution containing 1% normal 
goat  serum [The Jackson Laboratory])  was added,  and the blot 
was again incubated overnight at room temperature. Each immu- 
noblot was  then washed  and developed with a  chemilumines- 
cence kit from Dupont/New England Nuclear (Boston, MA). 
Heparin-Sepharose chromatography  (40) was  used  to  deter- 
mine whether  or  not plasma-localized  mMCP-7  was  properly 
folded  and associated  with  another protein.  200  ptl  of pooled 
plasma from FceRI-activated V3 mastocytosis mice were applied 
to a 1-ml column of heparin-Sepharose CL-6B (Pharmacia,  Pis- 
cataway,  NJ)  equilibrated in  100  mM  NaC1/10  mM  sodium 
phosphate,  pH 5.0 buffer. The bound proteins were eluted with a 
step gradient in which the NaC1 concentration of the buffer was 
sequentially increased to 200 mM, then to 300 raM, and finally to 
400 raM. Four 0.5-ml fractions were collected for each step; 0.1- 
ml  samples  of each  fraction were  applied  to  an  Immobilon-P 
membrane and  analyzed  for  the  presence  of immunoreactive 
mMCP-7, as described  above.  The protein content of each frac- 
tion was  also estimated  with a protein assay kit from Bio-Rad 
Laboratories. 
The major form of mMCP-7 in the plasma samples was iso- 
lated  by fast protein liquid chromatography (FPLC).  100 p~l of 
pooled plasma from FceRI-activated V3 mastocytosis mice were 
loaded on a Superose  12 HR. 10/30 gel filtration column (Phar- 
macia)  that  had  been  equilibrated in  150  mM  NaC1/10  mM 
EDTA/10 mM sodium phosphate,  pH  7.35.  The  column was 
eluted at a flow rate of~0.25 ml/min, and 0.25-0.5-ml fractions 
were collected and analyzed for the presence  of immunoreactive 
mMCP-7.  To  obtain its  NH2-terminal sequence,  the  fraction 
containing the most immunoreactive mMCP-7 was subjected to 
preparative  SDS-PAGE. Resolved proteins were transferred to an 
Immobilon-P membrane. One lane of the protein blot was ana- 
lyzed for the presence of immunoreactive mMCP-7. The other 
lane was briefly stained  with 0.5% Ponceau S (Sigma Chemical 
Co., St. Louis, MO). The 32-kD protein in this lane, which was 
recognized by anti-mMCP-7 Ig in the replicate blot, was excised, 
placed in the reaction cartridge  of a gas-phase sequencer (model 
470A;  Applied Biosystems,  Foster  City,  CA),  and subjected to 
automated Edman degradation at  the  Harvard  Microchemistry 
Facility. 
The spectrophotometric method of Svendsen et al.  (47) was 
used to determine whether or not plasma-localized  mMCP-7 is 
enzymatically active.  A  1-20-pL1 sample  of a plasma  or column 
fraction was placed in 1 ml ofa pH 7.6 buffer containing  25 mM 
sodium phosphate,  1 mM EDTA, and 50  p~g of tosyl-Gly-Pro- 
Lys-p-nitroanilide, benzoyl-Ile-Glu-Gly-Arg-p-nitroanihde,  acetyl- 
Ile-Glu-Ala-Arg-p-nitroanilide,  or D-Ile-Phe-Lys-p-nitroanilide. 
The change in optical  density at 405  nm was then measured at 
room temperature.  These  synthetic peptide substrates  were  se- 
lected because pancreatic  trypsin readily cleaves all four, whereas 
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equivalents ofBALB/c mBMMC using anti-mNICP-6 Ig. (A) The amino 
acid sequences ofpeptides 6 and 7 that correspond to residues 160-178 in 
mMCP-6 (2) and mMCP-7 (3), respectively. (Dash)  An identical amino 
acid. (/3) SDS-PAGE/immunoblot analysis oflysates ofmBMMC probed 
with anti-mMCP-6 Ig in the absence of any synthetic peptide (lane 1), or 
in the presence of peptide 6 (lane 2)  or peptide 7 (lane 3).  Molecular 
weight markers are indicated on the left. 
recombinant  mature  mMCP-7  selectively  degrades  tosyl-Gly- 
Pro-Lys-p-nitroanilide  (Huang,  C., 1K. Matsumoto, and 1K.L. Ste- 
vens, unpublished findings).  Each assay was standardized  with re- 
combinant mMCP-7. 
Comparative Protein Modeling and  Electrostatic Calculations for 
mMCP-6 and mMCP-7.  As described  previously for mMCP-1, 
mMCP-2, mMCP-4, mMCP-5, and mMCP-7 (39, 40), a three- 
dimensional  model  of mMCP-6  was  built  by  MODELLER-3 
(MODELLE1K is available by anonymous FTP from guitar.rocke- 
feller.edu  and also as part of QUANTA and INSIGHTII [MSI, 
San Diego, CA; e-mail blp@msi.com].) (48, 49) with the crystal- 
lographic structure of bovine pancreatic  trypsin  (Bookhaven Pro- 
tein  Data  Bank  code  2PTN)  (50) used  as  the  template.  The 
model of mMCP-6 passes all the stereochemistry checks imple- 
mented in the  program PIKOCHECK-3 (51). The electrostatic 
potentials  of mMCP-6 and mMCP-7 at pH 7.0 were calculated 
with the GRASP program (52), with standard  charges  from the 
CHARMM-22 force field (53). Each Lys and Arg residue was as- 
signed a positive  charge,  each Glu and Asp residue  was assigned a 
negative  charge,  and  each  His  residue  was  assigned  a  neutral 
charge. 
Results 
Histochemical and  Immunohistochemical Analyses  of  Tissue 
Mast Cells After Passive Systemic Anaphylaxis.  As assessed his- 
tochemically  and  immunohistochemically,  mMCP-6  and 
mMCP-7  are both present  in the methylene blue-staining 
granules  of the  mast  cells  that  reside  in  normal,  striated 
muscle-containing  tissues  such  as  the  tongue  (Fig.  2)  and 
heart (Fig. 3) of the BALB/c mouse. Both Abs stained non- 
activated  mast  cells  with  approximate  equal  intensity.  10- 
15 min after Ag was administered to IgE-sensitized BALB/c 
mice,  numerous  methylene  blue-staining  granule  cores 
were found outside  of most mast cells  in these two tissues. 
The  granule  cores  were  more  frequently  and  more  in- 
tensely stained by anti-mMCP-6  Ig than by anti-mMCP-7 
Ig.  Approximately  1  h  after Ag administration,  the  extra- 
cellular matrix adjacent to most activated tongue and heart 
mast cells still contained large numbers of granule cores that 
stained with methylene blue and anti-mMCP-6  Ig but not 
with anti-mMCP-7  Ig. 
To investigate the differential  fate of these granule  con- 
stituents in more depth after their release into the extracel- 
lular matrix,  V3 mastocytosis mice were  subjected  to pas- 
sive  systemic  anaphylaxis.  Spleen  and  liver  were  analyzed 
because  of their  large  content  of mMCP-6+/mMCP-7 + 
mast cells  (41). When IgE-sensitized V3 mastocytosis mice 
were given buffer alone intraperitoneally (n =  5), no meth- 
ylene  blue+/mMCP-6+/mMCP-7 +  granule  cores  were 
found  in  the  extracellular  matrix  of the  liver  (Fig.  4)  or 
spleen  (data  not shown).  The  granule  cores present  in the 
extracellular  matrix  10 min after systemic Ag challenge  of 
replicate IgE-sensitized mice were strongly stained by meth- 
ylene blue and by anti-mMCP-6  Ig (n  =  8).  Even though 
the  nonexocytosed granules in these  FcelKI-activated mast 
cells were readily stained by anti-mMCP-7  Ig, their exocy- 
tosed granule cores were only weakly stained by this Ab.  1 h 
after Ag challenge, large numbers of granule cores remained 
in  the  extracellular  matrix  that  were  stained  with  methy- 
lene  blue  and anti-mMCP-6  Ig but not anti-mMCP-7  Ig 
(Fig. 4). 
SDS-PAGE/Immunoblot  Analysis  of Plasma for  the  Two 
Mast  Cell  Tryptases and  Characterization  of Plasma-localized 
mMCP-7  by  Size,  Function, and  NH2-terminal  Amino  Acid 
Sequence.  SDS-PAGE/immunoblot  analysis  was  used  to 
determine whether or not any exocytosed mMCP-7 could 
make its way into the plasma of FceRI-activated V3 masto- 
cytosis mice.  No imnmnoreactive  mMCP-7  could be  de- 
tected in the plasma of normal BALB/c mice that had been 
induced  to  undergo  passive  systemic  anaphylaxis  (Fig.  5). 
However,  a  32-kD  protein  was  recognized  by  SDS- 
PAGE/immunoblot  analysis with  anti-mMCP-7  Ig in  the 
plasma  of IgE-sensitized V3  mastocytosis mice  10-20 min 
after Ag administration  (n  =  5)  (Fig. 5).  Although this im- 
munoreactive protein was still present in abundance  1 h af- 
ter systemic Ag administration, no immunoreactive mMCP-7 
was detected in the plasma after 4 h. In four of the five ex- 
periments,  the  level  of immunoreactive  mMCP-6  in  the 
plasma samples was below detection at all time points (Fig. 
5).  However,  in  a single  experiment,  a very small  amount 
of mMCP-6 was detected in plasma at the  1- and 4-h time 
points (data not shown). 
The  immunoreactive  protein  present  in  the  plasma  20 
min  after  the  administration  of Ag to  IgE-sensitized mice 
bound to a heparin-Sepharose  column that had been equil- 
ibrated  in  100  mM  NaC1/10  mM  sodium phosphate,  pH 
5.5.  Because  it dissociated from the  affinity column when 
the  NaC1 concentration  of the  buffer was  raised  to ~'-'300 
mM  (data  not  shown),  analogous  to  properly  folded  re- 
1064  Differential Tissue Retention of Mast Cell Tryptases Figure  2.  Immunohistochemical and histochemical analyses of the exocytosed tryptase/proteoglycan complexes remaining in the tongue around 
FceRI-activated mast cells. Serial sections of tongue tissue, prepared from IgE-sensitized normal BALB/c mice (a-c) or from IgE-sensitized normal 
BALB/c mice 10 rain (d-f) and 1 h (g-i) after Ag challenge, were stained with methylene blue (a, d, and g), anti-mMCP-7 Ig (b, e, and h), or anti- 
mMCP-6 Ig (c,f, and 0. (Arrows) Exocytosed granule cores in the extracellular matrix. 
combinant  pro  and  mature  mMCP-7  (40),  plasma-local- 
ized  mMCP-7  appeared  to  be  in  its  native  state  and  not 
associated  with  another  plasma  protein.  Furthermore, 
plasma samples  obtained within  30 min after Ag challenge 
of IgE-sensitized V3 mastocytosis mice readily cleaved to- 
syl-Gly-Pro-Lys-p-nitroanilide  but  not  benzoyl-Ile-Glu- 
Gly-Arg-p-nitroanilide,  acetyl-Ile-Glu-Ala-Arg-p-nitroanil- 
ide,  or  D-Ile-Phe-Lys-p-nitroanilide  (n  =  3).  Compared 
with  recombinant mMCP-7,  the amount of enzymatically 
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active  mMCP-7  in  the  different  plasma  samples  ranged 
from 50 to 500 Izg/ml. No tryptase activity was detected in 
the  plasma  of IgE-sensitized  V3  mastocytosis  mice  that 
were not challenged with Ag. 
Although  SDS-PAGE  immunoblot  analysis  indicated 
that  the  major form of mMCP-7  in  the  plasma  was ~-,32 
kD,  this  immunoreactive protein  and  the  tryptase  activity 
cochromatographed on the FPLC column as a broad peak 
with  an  apparent  average  molecular  mass  of ~-,150  kD, Figure 3.  Immunohistochemical and histochemical analyses  of the exocytosed tryptase/proteoglycan complexes remaining in the heart around FceRI- 
activated mast cells. Serial sections of heart tissue, prepared from IgE-sensitized normal BALB/c mice (a-c) or from IgE-sensitized normal BALB/c mice 
10 rain (d-f) and 1 h (g-i)  after Ag challenge, were stained with methylene blue (a, d, andg), anti-mMCP-7 Ig (b, e, and h), or anti-mMCP-6 Ig (c,f, and 
O. (Arrows)  Exocytosed granule cores in the extracellular matrix. 
whether  heparin  or  EDTA  (Fig.  6)  was  employed  as  the 
anticoagulant.  In  one  experiment,  the  serum  was  pooled 
from three mice and the FPLC fraction containing the peak 
level of the immunoreactive protein was  concentrated and 
subjected  to  preparative  SDS-PAGE.  After  transfer  to  an 
Immobilon-P  membrane  and  NH2-terminal  amino  acid 
analysis  of the  immunoreactive  32-kD  protein,  a  single 
prominent sequence oflle-Val-Gly-Gly-Gln-Glu-Ala-His- 
Gly-Asn-Lys-Trp-Pro-Trp was  obtained. This sequence is 
identical to the NH2-terminal amino acid sequence of ma- 
ture mMCP-7  deduced from its cDNA  and gene (3). 
FceRI-dependent Activation of BALB/c mBMMC and Evalu- 
ation of the Exocytosed Macromolecular Complexes for mMCP-6. 
Blots  previously  used  for  evaluating  the  extracellular  re- 
1066  Differential Tissue Retention of Mast Cell Tryptases Figure 4.  Immunohistochemical  and histochemical analyses of the exocytosed  tryptase/proteoglycan  complexes remaining in the liver around Fc~RI- 
activated V3-MC. Serial sections of  liver tissue, prepared from IgE-sensitized  V3 mastocytosis  mice (a-c) or from IgE-sensitized  V3 mastocytosis  mice 10 
rain (d-f) and 1 h (g-i)  after Ag challenge, were stained with methylene blue (a, d, and g), anti-mMCP-7 Ig (b, e, and h), or anti-mMCP-6 Ig (c,f, and 0. 
(Arrows) Exocytosed granule cores in the extracellular matrix. 
tention  of mMCP-5  and  mMCP-7  in  the  granule  core 
complexes  (40)  are now reported  for the concurrent find- 
ings  with  anti-m/VlCP-6  Ig.  In  these  in  vitro  studies, 
BALB/c  mBMMC  were  sensitized  with  anti-TNP  IgE, 
washed,  and  challenged  with  TNP-BSA.  The  FcePd-acti- 
vated mB/Vl/vlC were sedimented and samples of the result- 
ing  supernatants  were  applied  to  a  column  of Sepharose 
CL-2B  that  had  been  equilibrated  with  Tris-buffered  sa- 
line,  pH 7.2.  Protein blots containing samples of each col- 
umn fraction were analyzed not only as described  (40)  but 
also  with  anti-mMCP-6  Ig.  In  each  of four  experiments, 
the  majority  of immunoreactive  mMCP-6  filtered  in  the 
column's excluded volume (data not shown). 
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Comparative Protein Modeling and  Electrostatic Calculations 
for mMCP-6 and mMCpo 7.  The  backbone  structure  of 
the mMCP-6 model is virtually indistinguishable  from that 
of the  mMCP-7  model.  The  three-dimensional  model  of 
mMCP-6  suggests  that,  as  with  mMCP-7,  there  is  a 
trypsinlike  fold consisting of two  domains  with  the  active 
site  located  in  the  cleft  at  their  interface.  A  region  was 
identified on the surface of mMCP-6 away from the active 
site  that likely possesses  a  very strong positive  potential  at 
pH 7.0  (Fig.  7 A). This region contains seven Lys residues 
(gys  11, Lys  146, Lys  149, Lys  161, Lys  2~  Lys  2~  and Lys  223) and 
three  Arg  residues  (Arg  16~  Arg  186, and  Arg187). Whereas 
mMCP-7 has a His-rich region that is positively charged at Figure 5.  Time course of appearance and disappearance  ofimmunore- 
active mast cell tryptases in the circulation of FcdKI-activated mice. In 
the  depicted representative experiment, plasma samples were  collected 
from IgE-sensitized  normal BALB/c mice (lanes 1 and 2) and V3 masto- 
cytosis mice (lanes 3-7) at various time intervals after Ag administration. 
The samples were subjected to SDS-PAGE/immunoblot  analysis,  prob- 
ing with anti-mMCP-6 Ig or anti-mMCP-7  lg. 
the granule pH of 5.5  (40),  it lacks a Lys/Arg-rich region 
on any of its faces (Fig. 7  B). 
Discussion 
We now report on the preferential retention of mMCP-6 
in tissues and the preferential release of mMCP-7  into  the 
plasma  from  FcCRI-activated mast  cells  in  vivo.  Immu- 
noreactive mMCP-6  and mMCP-7  are each present in the 
granules of the mast ceils that reside in the tongue and heart 
of normal BALB/c mice (Figs. 2 and 3) and in the granules 
of the transformed mast ceils that develop in the liver and 
spleen of V3  mastocytosis mice  (Fig.  4).  10-15  rain  after 
Ag  was  administered  to  IgE-sensitized  normal  BALB/c 
mice  or  V3  mastocytosis  mice,  numerous  granule  cores 
composed of protease/proteoglycan macromolecular com- 
plexes were detected in the extracellular matrix adjacent to 
activated mast cells.  1  h  after passive systemic anaphylaxis, 
the  extracellular matrix  adjacent to  activated mast  cells in 
the  tongue  and  heart  of normal  mice  or in  the  liver and 
spleen of V3  mastocytosis mice still contained large num- 
bers  of  methylene  blue-staining  granule  cores  that  also 
contained immunoreactive mMCP-6.  In contrast, extracel- 
lular immunoreactive mMCP-7  was depleted by 10 min. 
BALB/c  mBMMC  express  mMCP-5  (54),  mMCP-6 
(2),  and  mMCP-7  (3).  When  supernatants  from  Fc~R.I- 
activated mBMMC  were chromatographed on a Sepharose 
CL-2B column, the majority ofimmunoreactive mMCP-5 
filtered in the column's excluded volume as a large macro- 
molecular complex with  serglycin proteoglycans,  whereas 
nearly  all  immunoreactive  mMCP-7  filtered  in  the  col- 
umn's  included volume  (40).  Analysis of replicate protein 
blots from these same experiments with  anti-mMCP-6  Ig 
revealed that in all experiments, the majority ofimmunore- 
active mMCP-6  filtered in the  column's excluded volume 
with mMCP-5  and serglycin proteoglycans. These in vitro 
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Figure 6.  FPLC ofmMCP-7 in the plasma of  V3 mastocytosis  mice. A 
plasma sample obtained from a FceP,  l-activated V3 mastocytosis mouse 
was applied to a FPLC-Superose column, and a sample of each 0.25-ml 
fraction was analyzed for tryptase enzymatic activity. The elution profile 
of three reference proteins, which possess molecular masses of 232, 158, 
and 67 kD, are depicted. Enzymatic activity was found only in fractions 
45-50; fraction 47 contained the maximal amount of enzymatic activity. 
The proteins in the remainder of each column fraction were precipitated 
with 10% TCA and assessed  by immunoblotting for mMCP-7  (inset).  lm- 
munoreactive mMCP-7  was found only in fractions 46-50;  fraction 48 
contained the maximal amount ofinmmnoreactive mMCP-7. 
findings again indicate that mMCP-7  differs from mMCP-6 
in  its  ability to  dissociate from  the  macromolecular com- 
plex even when exocytosed from an immature cell popula- 
tion of BALB/c mouse mast ceils. 
Because  of  the  tremendous  number  of  mMCP-6+/ 
mMCP-7 +  mast  ceils in  its  spleen  and  liver  (41),  the  V3 
mastocytosis  mouse  represented  a  more  suitable  in  vivo 
model system than the normal BALB/c mouse for assessing 
the fate of exocytosed tryptases beyond the tissue microen- 
vironment of the activated mast cell. In these mice, immu- 
noreactive mMCP-7 was abundant in the plasma 15 and 60 
min  (Fig.  5)  after  passive  systemic  activation.  Although 
mMCP-6  was  readily exocytosed from  spleen- and  liver- 
localized V3-MC,  little  or  no  mMCP-6  was  detected  in 
the plasma of the V3 mastocytosis mouse  (Fig. 5). Because 
mMCP-6  did  not  readily  dissociate from  the  exocytosed 
granule cores, it is presumed that the large size of the gran- 
ule core physically hinders the  movement  of the  complex 
of Mast Cell Tryptases Figure  7.  Comparison of the electrostatic prop- 
erties of  the homology models ofmMCP-6 (tl) and 
mMCP-7 (B) at neutral pH. The molecular surfaces 
of the models are  colored by the electrostatic po- 
tential, as shown by the color bar on each panel (in 
units of kT;  1 kT unit =  0.58 kcal/electron mol). 
(Yellow)  The  positively charged Lys and Arg resi- 
dues on this face of each tryptase.  (Black) The His 
residues. (Green) The active site in each protease. into  the  blood.  A  very small amount  of immunoreactive 
mMCP-6  was found in  the  circulation  at the  1- and 4-h 
time points in only one of five experiments. The failure to 
reproducibly detect mMCP-6 in plasma could be a conse- 
quence  of its  slower rate  of dissociation  from the  exocy- 
tosed  granule  cores  relative  to  mMCP-7.  However,  be- 
cause numerous cell types readily phagocytose exocytosed 
granule cores (55-58), its tighter association with the gran- 
ule  core might cause mMCP-6 to be catabolized by resi- 
dent cells in inflammatory sites along with other core-asso- 
ciated proteases. 
SDS-PAGE/immunoblot  analysis  revealed  that  plasma 
mMCP-7 is ~32  kD in its monomeric form (Fig.  6), like 
mBMMC-derived mMCP-7 (42). Whereas plasma mMCP-7 
is not covalently bound to a protease inhibitor,  the FPLC 
filtration data indicated that plasma-localized mMCP-7 ac- 
tually is ~150  kD.  The possibility has not been ruled out 
that plasma mMCP-7 is a monomer that is weakly associ- 
ated with another protein, but the gel filtration and heparin 
chromatography findings  suggest  that  this  mouse  tryptase 
circulates in the blood predominantly as a tetramer. A pre- 
ferred tetrameric state  for plasma mMCP-7  is  compatible 
with  the  original  description  of a  human  lung  mast  cell 
tryptase as a ~140-kD protease consisting of four 31-37-kD 
monomers (5,  6).  Immunoreactive mMCP-7  and tryptase 
activity exhibited  considerable  size  heterogeneity (Fig.  6). 
They were detected in the same FPLC fractions, but peak 
levels  of activity and  immunoreactive protein  differed by 
one fraction. Human lung mast cell tryptase exhibits maxi- 
mal activity as a tetramer (31).  IfmMCP-7 is also optimally 
active as a  tetramer,  one  explanation for the  one fraction 
difference is partial dissociation of the tetramer. 
mMCP-6  and  mMCP-7  share  71%  sequence  identity 
and have respective net charges of-5  and  -10  at neutral 
pH  (2-4).  Previous  homology modeling and  electrostatic 
potential calculations of mature mMCP-7 and site-directed 
mutagenesis analysis of recombinant pro-mMCP-7 revealed 
that mMCP-7  has a His-rich region on its surface (4,  40). 
This  region  appears to  enable  mMCP-7  to  interact  with 
serglycin proteoglycans inside the granule at pH 5.5. In ex= 
tracellular  spaces  at pH  >7.0,  His residues  are  neutral  in 
charge,  thereby allowing mMCP-7 to dissociate from ser- 
glycin proteoglycan and diffuse away from the exocytosed 
granule core. The reason for the retention of mMCP-6 in 
the  extracellular matrix may be explained by the apparent 
electrostatic potential around the tryptase. There is a surface 
region on mMCP-6 that has  10 positively charged Arg or 
Lys residues but no Asp or Glu residues  (Fig.  7).  The re- 
gion does not cover the active site,  although it ends in its 
vicinity. The region consists of several discontinuous chain 
segments  (e.g.,  the  three-dimensional  model predicts  that 
Lys  in  is adjacent to Lys  2~  and Lys  149 in mature mMCP-6). 
This structural feature probably ensures that only properly 
folded mMCP-6 molecules are stored in the granule bound 
to serglycin proteoglycan. The positively charged region in 
mMCP-6  does  not  overlap  with  any  of  the  positively 
charged domains in the mouse mast cell chymases (39)  or 
mMCP-7  (40).  Unlike  the  His-containing  proteoglycan- 
binding region of mMCP-7, the mMCP-6 region remains 
positively charged at pH >7.0, thereby preventing the dis- 
sociation of mMCP-6 from the exocytosed macromolecu- 
lar complex. 
NH2-terminal amino acid and functional (Fig.  6)  analy- 
ses  indicated  that  the  immunoreactive  mMCP-7  in  the 
plasma of the FceRI-activated V3 mastocytosis mouse is a 
mature, active enzyme rather than pro=mMCP-7.  It is not 
degraded and is not covalently bound to a protease inhibi- 
tor. Although mast cell tryptases purified from the human 
lung  are  somewhat  resistant  to  inactivation  by  plasma- 
localized protease inhibitors  (6,  31),  at least one  rat  mast 
cell tryptase readily binds the inter-e~-trypsin inhibitor (59, 
60)  and otl-macroglobulin (61) families ofprotease inhibi- 
tors.  Such  a pathway could  exist in BALB/c  mice but  is 
overwhelmed by the superimposition of the mastocytosis. 
However,  because  mMCP-7  circulates  as  a  multimeric 
complex rather than as a monomer (Fig.  6), it also could be 
sterically  resistant  to  inactivation  by  protease  inhibitors. 
Monomeric  mMCP-7  possesses  some  unique  structural 
features that  may hinder  its  covalent entrapment by pro- 
tease inhibitors.  The lower preponderance of Lys residues 
on the surface ofmMCP-7 (3, 4, 40), coupled with its high 
degree of glycosylation (42),  might prevent the formation 
of  covalent  bonds  with  the  reactive  y-Glu  residues  of 
cx-macroglobulins.  In  addition,  protein-modeling  studies 
(4,  40)  revealed that  mature mMCP-7  has  a surface loop 
that extends into the active site that could restrict its sub- 
strate specificity and  also  prevent cleavage of the  bait re- 
gions of various protease inhibitors. 
Mouse and human mast cells  express at least two  tryp- 
rases. Based on an ELISA, as much as 88 ng/ml of a human 
mast cell tryptase has been found in the sera of some pa- 
tients  with  mastocytosis and  of some patients  undergoing 
systemic anaphylaxis (62,  63).  The amount of this immu- 
noreactive protein was insufficient for biochemical charac- 
terization,  but  the  finding  in  the  mouse  that  mMCP-7 
selectively  dissociates  from  extracellular-localized  granule 
cores raises the possibility that in other species there is a dif- 
ferential processing of the distinct tryptases in inflammatory 
sites around activated mast cells. Whereas mMCP-6 is pre= 
sumed to  act locally, perhaps in  concert with other com- 
plexed  secretory  granule  proteases,  enzymatically  active 
mMCP-7 could set up a transient protease gradient in the 
inflammatory  site  to  allow  for  proliferation  (18,  19)  or 
chemotaxis (64) of other cell types through a mMCP-7-acti- 
vated receptor,  such  as those  identified for thrombin  (65) 
and trypsin (66). 
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